# Stryker to announce second quarter 2026 financial results
Canonical URL: https://biopharmsignal.com/news/SYK/stryker-to-announce-second-quarter-2026-financial-results-94b73874
Ticker: SYK
Company: Stryker
Source: Stryker
Published: 2026-07-01 12:00 EST
Original Source URL: https://investors.stryker.com/press-releases/news-details/2026/Stryker-to-announce-second-quarter-2026-financial-results/default.aspx
## Summary

Portage, Michigan, July 01, 2026 (GLOBE NEWSWIRE) - Stryker (NYSE: SYK) will host a webcast at 4:30 p.m. (Eastern time) on Thursday, July 30, 2026 , to discuss its second quarter 2026 financial results. The live webcast can be accessed at Stryker - Events Presentations . An archive of the webcast will also be available at Stryker’s website beginning approximately two hours after the live call ends. An accompanying press release that includes summary financial information for the second quarter will be issued at approximately 4:05 p.m. (Eastern time) and available at Stryker - Press Releases on the day of the webcast. About Stryker Stryker is a global leader in medical technologies and, together with our customers, we are driven to make healthcare better. We offer innovative products and services in MedSurg, Neurotechnology and Orthopaedics that help improve patient and healthcare outcomes. Alongside our customers around the world, we impact more than 150 million patients

## Article Body
Portage, Michigan, July 01, 2026 (GLOBE NEWSWIRE) -- Stryker (NYSE: SYK) will host a webcast at 4:30 p.m. (Eastern time) on Thursday, July 30, 2026 , to discuss its second quarter 2026 financial results. The live webcast can be accessed at Stryker - Events & Presentations . An archive of the webcast will also be available at Stryker’s website beginning approximately two hours after the live call ends.

An accompanying press release that includes summary financial information for the second quarter will be issued at approximately 4:05 p.m. (Eastern time) and available at Stryker - Press Releases on the day of the webcast.

About Stryker

Stryker is a global leader in medical technologies and, together with our customers, we are driven to make healthcare better. We offer innovative products and services in MedSurg, Neurotechnology and Orthopaedics that help improve patient and healthcare outcomes. Alongside our customers around the world, we impact more than 150 million patients annually. More information is available at www.stryker.com.

Contacts

For investor inquiries: Nick Mead, Vice President, Investor Relations at 269-385-2600 or nick.mead@stryker.com

For media inquiries: Kim Montagnino, Vice President, Chief Communications Officer at 269-385-2600 or kim.montagnino@stryker.com

Source: Stryker Corporation
## Recent Company News
- 2026-07-01 12:00 EST — [Stryker to announce second quarter 2026 financial results](https://biopharmsignal.com/news/SYK/stryker-to-announce-second-quarter-2026-financial-results-94b73874) — Source: Stryker
- 2026-06-25 13:46 EST — [Stryker completes acquisition of Amplitude Vascular Systems to add next-generation IVL technology to peripheral vascular portfolio](https://biopharmsignal.com/news/SYK/stryker-completes-acquisition-of-amplitude-vascular-systems-to-add-next-generation-ivl-technology-to-peripheral-vascular-portfolio) — Source: Stryker
- 2026-06-25 13:46 EST — [Stryker to announce financial results for its fourth quarter and full year 2025](https://biopharmsignal.com/news/SYK/stryker-to-announce-financial-results-for-its-fourth-quarter-and-full-year-2025) — Source: Stryker
- 2026-06-25 13:46 EST — [Stryker reports 2025 operating results and 2026 outlook](https://biopharmsignal.com/news/SYK/stryker-reports-2025-operating-results-and-2026-outlook) — Source: Stryker
- 2026-06-25 13:46 EST — [Stryker declares an $0.88 per share quarterly dividend](https://biopharmsignal.com/news/SYK/stryker-declares-an-0-88-per-share-quarterly-dividend) — Source: Stryker
## Related News
- 2026-07-21 12:00 EST — MOR — [Novartis delivered sales growth in Q2 and further advanced the pipeline; Full-year guidance reaffirmed](https://biopharmsignal.com/news/MOR/novartis-delivered-sales-growth-in-q2-and-further-advanced-the-pipeline-full-yea-63a32b47)
- 2026-07-21 10:28 EST — GSK — [ViiV Healthcare to present phase IIIb data comparing Dovato with Biktarvy in treatment-naïve adults alongside INSTI-powered long-acting injectable innovation at AIDS 2026](https://biopharmsignal.com/news/GSK/viiv-healthcare-to-present-phase-iiib-data-comparing-dovato-with-biktarvy-in-tre-1ff3f640)
- 2026-07-20 20:05 EST — RANI — [Rani Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/RANI/rani-therapeutics-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-ec56b3b0)
- 2026-07-20 14:53 EST — IPHA — [Innate Pharma announces Completion of Enrollment in Phase 1 Dose Escalation Study of IPH4502, a Novel Nectin-4 Exatecan Antibody-Drug Conjugate (ADC)](https://biopharmsignal.com/news/IPHA/innate-pharma-announces-completion-of-enrollment-in-phase-1-dose-escalation-stud-0778493f)
- 2026-07-20 13:05 EST — ACAD — [Acadia Pharmaceuticals Receives FDA Fast Track Designation for Remlifanserin in Alzheimer's Disease Psychosis](https://biopharmsignal.com/news/ACAD/acadia-pharmaceuticals-receives-fda-fast-track-designation-for-remlifanserin-in--f36b622c)